跳至主要内容
临床试验/2025-523121-17-00
2025-523121-17-00招募中4 期

Multicenter clinical trial on the effectiveness and safety of outpatient treatment of acute uncomplicated diverticulitis without antibiotics versus antibiotic treatment. ADIANA Trial.

Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia5 个研究点 分布在 1 个国家目标入组 282 人开始时间: 2026年3月1日最近更新:
干预措施

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
282
试验地点
5

研究概览

简要总结

To evaluate the effectiveness and safety of outpatient treatment without antibiotics compared to outpatient treatment with antibiotics in patients with uncomplicated acute diverticulitis.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Patients over 18 years of age with a clinical and radiological diagnosis of uncomplicated acute diverticulitis of the sigmoid colon or descending colon (left-sided AD).
  • Radiological diagnosis of acute uncomplicated diverticulitis by CT scan (modified Hinchey classification 0-Ia).
  • First episode or previous history of AD (both complicated and uncomplicated, and ≥6 months having elapsed since the last episode to the current clinic visit).
  • Signing of the informed consent form to participate in the study

排除标准

  • Age >70 years old
  • Patients who are candidates for hospitalization and/or intravenous antibiotic therapy (at diagnosis): Repeated vomiting or oral intolerance, need for intravenous fluid therapy and/or close monitoring, temperature >38°C, deterioration of general condition, and/or clinical suspicion of sepsis.
  • Significant or decompensated comorbidity (ASA classification IV).
  • Immunocompromised patients: Hematological causes, HIV with low CD4+ levels, immunosuppressive treatment, prolonged treatment with corticosteroids, chemotherapy, transplant or splenectomy patients, predisposing genetic disorders (severe combined immunodeficiency, etc.).
  • Oral or intravenous antibiotic therapy in the 2 weeks prior to the onset of symptoms, for another cause.
  • Inflammatory bowel disease (Crohn's disease, ulcerative colitis).
  • Lack of social support that makes outpatient treatment impossible.

研究组 & 干预措施

ciprofloxacino cinfa 500 mg comprimidos recubiertos EFG

Test

干预措施: ciprofloxacino cinfa 500 mg comprimidos recubiertos EFG (Drug)

amoxicilina/ácido clavulánico cinfa 875 mg/125 mg comprimidos recubiertos con película EFG

Test

干预措施: amoxicilina/ácido clavulánico cinfa 875 mg/125 mg comprimidos recubiertos con película EFG (Drug)

cefuroxima cinfa 250 mg comprimidos recubiertos con película EFG

Test

干预措施: cefuroxima cinfa 250 mg comprimidos recubiertos con película EFG (Drug)

MEIACT 200 mg comprimidos recubiertos con película

Test

干预措施: MEIACT 200 mg comprimidos recubiertos con película (Drug)

ciprofloxacino cinfa 750 mg comprimidos recubiertos EFG

Test

干预措施: ciprofloxacino cinfa 750 mg comprimidos recubiertos EFG (Drug)

Metronidazol Normon 250 mg comprimidos EFG

Test

干预措施: Metronidazol Normon 250 mg comprimidos EFG (Drug)

研究者

发起方
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
申办方类型
Educational Institution
责任方
Principal Investigator
主要研究者

María Muñoz García

Scientific

Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

研究点 (5)

Loading locations...

相似试验